- How decentralized and hybrid solutions can be used to increase patient access to clinical trials
- In-home visits have benefits for participants, sites and sponsors
- How to ensure uptake and adoption to drive global results
- What’s next for the hybrid trial model
Archives: Agenda
KEYNOTE PANEL DISCUSSION: Navigating the current geo-political landscape as a small biotech
- Overviewing the current political landscape and understanding what the impact is on small biotech’s
- Adapting to change by effectively navigating a small biotech though uncertainty
- Understanding and leveraging new start-up opportunities by reviewing investment and marketing trends
PRIZE DRAW
Visit our exhibitors’ booths throughout the day and collect stamps in order to enter our Prize Draw and be in for a chance of winning Apple devices or Amazon giftcards. The Prize Draw will take place in the Exhibition Hall. Make sure you don’t miss out!
Tempus Ecosystem combines for smarter insight to precision medicine oncology trials
- Utilize multi-omics data from next-generation sequencing to build a smarter, data-driven trial design.
- Accelerate patient matching and enrollment through our extensive clinical trial site network.
- Combine these capabilities in an integrated ecosystem to build a better, more efficient clinical trial.
Designed to deliver: Unlocking the value of bespoke outsourcing models
- Move from siloed to integrated with a collaborative framework and culture
- Build an agile operating model for immediate and long-term success
- Unlock the value of strategic FSP: key examples of success
Afternoon refreshments and networking
Strategies for success when every patient counts: enhancing retention and protocol compliance in ultra-rare and genetic disorders
- In rare populations, every patient carries significant weight, making retention more critical than in most other therapeutic areas.
- Because patient numbers are extremely limited, attrition cannot be absorbed—losing even a single participant can jeopardize the entire study.
- Rare disease trials often focus heavily on recruitment, but retention is equally essential and frequently overlooked.
- Collaboration with the Community is key
- Case studies
Chair’s closing remarks and end of conference
Leverage the power of AI to optimize study site and CRA performance
- Growing trial complexity increases site questions and strains CRA resources
- RASPberry AI™ provides instant, accurate access to study-specific information
- Rapid answers improve site performance and CRA productivity
- Sponsors gain actionable insights into trial execution